 | | PRD_001215 | | Name: | Macrocyclic Inhibitor (3R,6S,9S,12E,16S)-9-(3-AMINO-3-OXO-PROPYL)-3-[(4-BENZOYLPHENYL)METHYL]-6-(CYCLOHEXYLMETHYL)-2,5,8,11,14-PENTAOXO-1,4,7,10,15-PENTAZACYCLOICOS-12-ENE-16-CARBOXAMIDE | | Formula: | C40 H48 N7 O9 | | Definition date: | 2014-05-21 | | Last modified: | 2023-11-03 |
|
 | | PRD_001238 | | Name: | PEPSTATIN ANALOGUE ISOVALERYL-VAL-VAL-STA-O-ET | | Formula: | C25 H47 N3 O6 | | Definition date: | 2014-06-04 | | Last modified: | 2017-05-04 |
|
 | | PRD_001163 | | Name: | N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamyl-L-glutamic acid | | Formula: | C34 H40 N10 O15 | | Definition date: | 2014-06-18 | | Last modified: | 2017-09-14 |
|
 | | PRD_001164 | | Name: | N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-glutamic acid | | Formula: | C29 H33 N9 O12 | | Definition date: | 2014-06-18 | | Last modified: | 2017-09-14 |
|
 | | PRD_001165 | | Name: | N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-gamma-glutamyl-L-glutamic acid | | Formula: | C24 H26 N8 O9 | | Definition date: | 2014-06-18 | | Last modified: | 2017-09-14 |
|
 | | PRD_001237 | | Name: | Boc-Ala-Ala-Ala-Al-CHO | | Formula: | C14 H27 N3 O5 | | Definition date: | 2014-06-18 | | Last modified: | 2023-11-03 |
|
 | | PRD_001078 | | Name: | Peptide inhibitor MPT-DPP-DAR-G-DPN-NH2 | | Formula: | C23 H38 N9 O5 S | | Definition date: | 2014-06-25 | | Last modified: | 2014-06-25 |
|
 | | PRD_001161 | | Name: | N-hexanoyl-L-valyl-N~1~-[(4S,5S,6R)-5-hydroxy-2,6-dimethyloctan-4-yl]-N~5~,N~5~-dimethyl-L-glutamamide | | Formula: | C28 H54 N4 O5 | | Description: | Originated from (S)-N1-((S,Z)-2,6-dimethyl-5-oxooct-6-en-4-yl)-2-((S)-2-hexanamido-3-methylbutanamido)-N5,N5-dimethylpentanediamide that reacts with N-terminal Thr of the protein, opening double bonds of the original compound and making two covalent linkages with the amino group and side chain hydroxyl of the Thr. The PRD represents the bound form. | | Definition date: | 2014-07-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001171 | | Name: | Serine protease inhibitor BEZ-NLE-LYS-ARG-M9P | | Formula: | C32 H57 F3 N11 O5 | | Definition date: | 2014-07-08 | | Last modified: | 2014-07-08 |
|
 | | PRD_002092 | | Name: | L-alanyl-3,5-dibromo-L-tyrosyl-L-alanine | | Formula: | C15 H19 Br2 N3 O5 | | Definition date: | 2014-07-08 | | Last modified: | 2014-07-08 |
|
 | | PRD_002101 | | Name: | N-[(6R,9S,10R,13S,15aR,22S,24aR)-22-[4-(dimethylamino)benzyl]-6-ethyl-10,23-dimethyl-18-(morpholin-4-ylmethyl)-5,8,12,15,21,24-hexaoxo-13-phenyl-1,2,3,5,6,7,8,9,10,13,14,15,15a,16,19,21,22,23,24,24a-icosahydro-12H-pyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hydroxypyridine-2-carboxamide | | Formula: | C50 H63 N9 O10 | | Definition date: | 2014-07-30 | | Last modified: | 2014-07-30 |
|
 | | PRD_001244 | | Name: | N-[(benzyloxy)carbonyl]-L-leucyl-N-{(2S,3S)-1-[(2,4-dimethylphenyl)amino]-2-hydroxy-5-methyl-1-oxohexan-3-yl}-L-leucinamide | | Formula: | C35 H52 N4 O6 | | Definition date: | 2014-08-13 | | Last modified: | 2017-09-14 |
|
 | | PRD_001158 | | Name: | Teicoplanin pseudoaglycone | | Formula: | C78 H79 Cl2 N9 O32 | | Definition date: | 2014-09-03 | | Last modified: | 2014-09-03 |
|
 | | PRD_001169 | | Name: | Teicoplanin pseudoaglycone | | Formula: | C88 H97 Cl2 N9 O33 | | Definition date: | 2014-09-03 | | Last modified: | 2014-09-03 |
|
 | | PRD_001230 | | Name: | D-valyl-N-[(2S,3S)-7-amino-1-chloro-2-hydroxyheptan-3-yl]-L-leucinamide | | Formula: | C18 H37 Cl N4 O3 | | Definition date: | 2014-09-03 | | Last modified: | 2017-09-14 |
|
 | | PRD_001231 | | Name: | L-phenylalanyl-N-[(2S,3S)-6-carbamimidamido-1-chloro-2-hydroxyhexan-3-yl]-L-phenylalaninamide | | Formula: | C25 H35 Cl N6 O3 | | Definition date: | 2014-09-03 | | Last modified: | 2017-09-14 |
|
 | | PRD_002089 | | Name: | (1R,2S,19S,22R,34S,37R,40S,52S)-2-{[(2R,3S,4R,5R,6R)-3-(acetylamino)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-22-amino-5,15-dichloro-64-({(2R,3R,4S,5S,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(8-methylnonanoyl)amino]tetrahydro-2H-pyran-2-yl}oxy)-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-{[(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-7,13,28-trioxa-20,36,39,53,55,58-hexaazaundecacyclo[38.14.2.2~3,6~.2~14,17~.2~19,34~.1~8,12~.1~23,27~.1~29,33~.1~41,45~.0~10,37~.0~46,51~]hexahexaconta-3,5,8(64),9,11,14,16,23(61),24,26,29(60),30,32,41(57),42,44,46,48,50,62,65-henicosaene-52-carboxylic acid (non-preferred name) | | Formula: | C88 H97 Cl2 N9 O33 | | Definition date: | 2014-09-10 | | Last modified: | 2014-09-10 |
|
 | | PRD_001222 | | Name: | bicyclic peptide UK601 (bicyclic 1) | | Formula: | C59 H101 N24 O17 S4 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
 | | PRD_001223 | | Name: | bicyclic peptide UK602 (bicyclic 1) | | Formula: | C56 H96 N23 O16 S4 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
 | | PRD_001224 | | Name: | bicyclic peptide UK603 (bicyclic 1) | | Formula: | C59 H101 N24 O17 S4 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
 | | PRD_001225 | | Name: | bicyclic peptide UK604 (bicyclic 2) | | Formula: | C56 H96 N23 O16 S4 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
 | | PRD_001226 | | Name: | bicyclic peptide UK607 (bicyclic) | | Formula: | C64 H110 N25 O18 S4 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
 | | PRD_001227 | | Name: | bicyclic peptide UK603 (bicyclic 2) | | Formula: | C59 H101 N24 O17 S4 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
 | | PRD_001232 | | Name: | Alpha-conotoxin ImI mutant | | Formula: | C54 H84 N20 O15 S4 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
 | | PRD_001251 | | Name: | ACE-PHE-ALA-THR-ALA-0QE | | Formula: | C22 H31 Cl N4 O6 | | Definition date: | 2014-09-24 | | Last modified: | 2014-09-24 |
|
